Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes

NARecruitingINTERVENTIONAL
Enrollment

2,714

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

August 23, 2027

Study Completion Date

August 23, 2028

Conditions
Diabetes Mellitus, Type 2Cardiovascular DiseasesDiabetic Nephropathy Type 2
Interventions
DEVICE

Polygenic Risk Score

The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.

Trial Locations (2)

H2X 0A9

RECRUITING

CHUM, Montreal

H3S 1Z5

NOT_YET_RECRUITING

ELNA Medical, Montreal

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genome Quebec

OTHER

collaborator

Genome Canada

OTHER

collaborator

ELNA Medical

UNKNOWN

lead

Optithera

INDUSTRY